Creative Innovation For Better Healthy Life

Press release

Title GL PharmTech successfully completes Phase Ⅰ clinical trial of IMD for opioid analgesic, Oxycodone
Poster Admin Date 2013-08-08 Hit 2368

buy amoxicillin without prescription

buy amoxicillin online

amoxicillin price without prescription

buy amoxicillin from canada click

where can i buy naltrexone

buy low dose naltrexone go


remeron redirect







buy naltrexone

how to buy naltrexone read here

abortion procedures first trimester

first trimester abortion

mixing viagra and weed

mixing viagra and weed

is naloxone and naltrexone the same

naloxone versus naltrexone opioid go

ventolin over the counter nsw

ventolin side effects

bentelan fiale 4 mg

bentelan prezzo

naltrexone implant reviews

naltrexone reviews for opiate addiction go

viagra prodej

viagra prodej brno

abortion cost without insurance

click abortions cost link

abortion cost without insurance

click abortions cost link

Once-daily IMD with modified usage and dosage of the conventional opioid analgesic

GL PharmTech (CEO, Hun Sik Wang) drew an attention from incrementally modified drug(IMD) development as the company has successfully completed Phase I clinical study of GL2907 Tab., IMD with modified usage and dosage of the conventional opioid analgesic, Oxycodone, submitting the report to the MFDS.

Two Phase Ⅰ clinical trials were conducted. One was a randomized, open-label, single-dose, cross-over study on clinical pharmacology and dietary influence, and the other was a study to compare pk profiles of GL2907 vs. Oxycontine CR 10mg Tab.(Mundipharma) via repeated administration in healthy male adults.

Oxycodone belongs to opioid analgesics (Morphine, Heroin, Codeine), and is a semisynthetic opioid analgesic that acts on the central nervous system. It has an analgesic effect by directly binding to opioid receptors. Due to low first-pass effect during oral administration, it has higher bioavailability and lower variation between species. Thus, it is effective in the control of intermediate and severe pain which requires treatment with opioid analgesics.

Compared to the conventional drug that is administered daily twice, GL2907 Tab., which was developed by GL PharmTech as an once-daily drug, has advantages of improving drug compliance,  maximizing analgesic effect by constantly maintaining blood oxycodone concentration, and  reducing the occurrence rate of adverse events due to stable profiles. Thus, GL2907 is expected to significantly improve the quality of life in patients who require ATC(Around-the-clock) pain control.

"When pk profiles were compared between GL2907 and the conventional twice-daily drug, Oxycontine CR Tab 10mg, the same bioequivalence was obtained for Cmax and AUC. Once the report of this trial is completed, we plan to file GL2907 Tab. 20mg approval for marketing this year. In addition, we will file IND for Phase Ⅰ clinical study of GL2907 40mg and 80 mg.” CEO Mr. Wang said.